Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Pharm Sci. 2009 May 12;37(2):67-75. doi: 10.1016/j.ejps.2009.01.007. Epub 2009 Jan 30.

P2 purinergic signalling in the pancreatic beta-cell: control of insulin secretion and pharmacology.

Author information

1
Montpellier I University and CNRS UMR 5232, Centre for Pharmacology and Innovation in Diabetes, Montpellier, France. pierre.petit@univ-montp1.fr

Abstract

Extracellular adenosine triphosphate is able to modulate pancreatic beta-cell function, acting on P2 purinergic ionotropic (P2X) and metabotropic (P2Y) receptors. Physiologically, ATP entrains beta-cells into a common rhythm by coordinating Ca(2+) oscillations; it plays a central role in insulin secretion pulsatility. ATP also triggers a positive feedback signal amplifying glucose-induced insulin release, which argues for a potential pharmacological application. ATP has consistently been shown to increase cytoplasmic free calcium concentration, notably in human tissue. Acting on P2X receptors, of which different molecular subtypes are expressed in beta-cells, it leads to a transient insulin release that may involve a closure of K(ATP) channels or a rapidly decaying inward current. Activation of G-protein-coupled P2Y receptors triggers different signalling pathways and amplifies insulin release in a glucose-dependent way. It has recently been shown that pancreatic beta-cells express different molecular subtypes of receptors, which may explain the complex interaction of P2Y ligands on high- and low-affinity binding sites. Despite the complexity of this purinergic pharmacology, consistent pre-clinical data suggest the potential of P2Y receptor agonists as drug candidates for type 2 diabetes.

PMID:
19429412
DOI:
10.1016/j.ejps.2009.01.007
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center